Eli Lilly's stock price surged following impressive late-stage trial results for its next-generation weight-loss drug. The company also reported that its drug Jaypirca significantly reduced the risk of disease progression in CLL/SLL patients. Furthermore, Eli Lilly expanded its portfolio by acquiring 4E Therapeutics, a developer of non-addictive painkillers.
